EEI-BIOTECHFINANCES Eléments Essentiels d'Information / Essential Elements of Information
Tuesday, October 22nd 2019 at 1:00pm UTC NOTTINGHAM, England–(BUSINESS WIRE)– Quotient Sciences, the innovative drug development and manufacturing organization, today announces the appointment of Claes Glassell as non-executive chairman of its board of directors. A highly accomplished leader in the pharmaceutical industry with over 35 years’ experience, Glassell has held …
Plus »Cystic Fibrosis Foundation Statement on FDA Approval of TRIKAFTA, the First Triple-Combination Therapy for the Most Common CF Mutation
Monday, October 21st 2019 at 10:01pm UTC BETHESDA, Md.–(BUSINESS WIRE)– Today’s FDA approval of TRIKAFTA (elexacaftor/ivacaftor/tezacaftor), the highly effective and highly anticipated triple-combination CFTR modulator, marks the start of a new era in cystic fibrosis. This medicine represents the single greatest therapeutic advancement in the history of CF, offering a …
Plus »Takeda obtient une licence pour le traitement de la maladie cœliaque de première classe de COUR Pharmaceuticals à la suite d’une étude de validation de principe positive de phase 2a
Tuesday, October 22nd 2019 at 6:15pm UTC ? Les données les plus récentes d’une étude de phase 2a présentée lors de la UEG Week 2019, à Barcelone, en Espagne, soulignent le potentiel de la médecine expérimentale pour prévenir l’activation immunitaire induite par le gluten chez les patients atteints de la …
Plus »STALICLA nomme Stéphane Baudouin au poste de responsable scientifique
Tuesday, October 22nd 2019 at 7:34pm UTC Le neurobiologiste met ses 10 années d’expérience dans les Troubles du Spectre Autistique au service de la stratégie de recherche de la startup Biotech Suisse GENÈVE–(BUSINESS WIRE)– STALICLA est ravie d’annoncer la nomination de Stéphane Baudouin au poste de responsable scientifique à compter …
Plus »Global Cell Harvesting Markets Through 2019-2025 | Anticipating a CAGR of 8.4% During the Forecast Period – ResearchAndMarkets.com
Tuesday, October 22nd 2019 at 5:04pm UTC DUBLIN–(BUSINESS WIRE)– The « Cell Harvesting – Market Analysis, Trends, and Forecasts » report has been added to ResearchAndMarkets.com’s offering. The Cell Harvesting market worldwide is projected to grow by US$157.2 Million, driven by a compounded growth of 8.4%. Manual Cell Harvesters, one of the …
Plus »Systems Oncology Receives Investment from The Pritzker Organization
Tuesday, October 22nd 2019 at 1:00pm UTC SCOTTSDALE, Ariz.–(BUSINESS WIRE)– Systems Oncology, LLC (“SO”) and The Pritzker Organization, LLC (“TPO”) announced today that Pritzker Family Business Interests advised by TPO have invested in the first closing of SO’s Series B round. The funding will be used to invest in both …
Plus »Takeda adquiere la licencia de la innovadora terapia para la enfermedad celíaca de COUR Pharmaceuticals después de un estudio positivo de fase 2a de prueba de concepto
Tuesday, October 22nd 2019 at 1:29pm UTC ? Datos de última hora de un estudio de fase 2a presentados en la UEG Week 2019, Barcelona, España, destacan el potencial de un fármaco en investigación para prevenir la activación inmunitaria inducida por el gluten en pacientes con enfermedad celíaca ? Takeda …
Plus »Sonnet BioTherapeutics Selects Abzena as Clinical Stage Manufacturing Partner for its IL-12-FHAB cytokine-derived Therapeutic Candidate
Tuesday, October 22nd 2019 at 1:28pm UTC PRINCETON, N.J. & SAN DIEGO–(BUSINESS WIRE)– Sonnet BioTherapeutics Inc., a clinical stage biopharmaceutical developing innovative targeted biologic drugs, announced today that it has selected Abzena as its manufacturing partner for SON-1010, an IL-12-FHAB cytokine, in preparation for clinical development. SON-1010 uses Sonnet’s proprietary …
Plus »Venarum Medical Receives Ongoing NIH SBIR Grant Support for its EndoVenous Valve System Development
Monday, October 21st 2019 at 7:44pm UTC Ongoing NIH SBIR Support Enables Progress Towards a Prosthetic Venous Valve EATONTOWN, N.J.–(BUSINESS WIRE)– Venarum Medical, LLC today announced receipt of a mentorship grant in further support of its awarded Phase II SBIR Grant “EVVS: EndoVenous Valve System” currently underway. Under its Phase …
Plus »Moderna to Report Third Quarter 2019 Financial Results on Wednesday, November 6th, 2019
Tuesday, October 22nd 2019 at 12:00pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call and webcast at 8:00 …
Plus »
